HLA-B27 and CYP2D6*4 polymorphism prevalence analysis in Turkey
Main Article Content
Keywords
HLA-B27, cytochrome P450, CYP2D6*4, polymorphism
Abstract
ÖZ
Arka plan: HLA-B27 pozitifliği, spondiloartropatilerin, bazı otoinflamatuar ve nörolojik hastalıkların ve farklı kanser türlerinin etiyopatogenezinden sorumlu tutulmaktadır. Sitokrom P450 alt aile grubundan CYP2D6, tedavide kullanılan ilaçların% 25'inin metabolizmasında rol oynar. CYP2D6 * 4 polimorfik allellerinin terapötik ilaçlar üzerinde farklı etkilere neden olabileceğinin bilincinde olan bu değişken, tedaviye yanıt vermemesi, yan ilaç etkilerinin gözlemlenmesi ve birçok hastalığın araştırılmasında değerdir. Bu sayfada, polimorfik sitokrom P450 enzimleri ve CYP2D6 * 4 allellerinde etnik kökene bağlı genetiklerin analizi için Türkiye'nin Orta Karadeniz Bölgesinde HLA-B27 ve CYP2D6 * 4 prevalansını araştırdık.
Gereç ve Yöntemler: Çalışmaya toplam 1068 sağlıklı birey dahil edildi ve HLA-B27 ve CYP2D6 * 4 polimorfizmleri incelendi. Genes-4U kiti ve Tib-Molbiol kiti kullanıldı. Analiz için LightCycler 480 II Real Time PCR termal döngüleyici kullanıldı.
Bulgular: HLA-B27 ve CYP2D6 * 4 polimorfizm analizinde toplam 1068 örnek çalışıldı. HLA-B27 polimorfizm pozitifliği 86 (% 8,9) örnekte tespit edildi. CYP2D6 * 4 polimorfizminde, 203 (% 19.09) örnekte heterozigot alleller ve 26 (% 2.44) örnekte homozigot alleller tespit edildi. 29 (% 2,71) örnek hem HLA-B27 hem de CYP2D6 * 4 polimorfizmlerini taşırken.
Sonuç: Çalışmamızda, diğer sağlıklı popülasyonların verilerine benzer bir oranda polimorfizm ve alel frekanslarının sıklığını belirledik.
Anahtar kelimeler: HLA-B27, sitokrom P450, CYP2D6 * 4, polimorfizm
References
1. Kelley J, Walter L, Trowsdale J. Comparative genomics of major histocompatibility complexes. Immunogenetics 2005;56(10):683-95.
2. Khan M A. Remarkable polymorphism of HLA-B27: an ongoing saga. Curr Rheumatol Rep 2010;12(5):337-41.
3. Khan M A. HLA-B27 and its pathogenic role. J Clin Rheumatol 2008;14(1):50-2.
4. Petty R E. HLA-B27 and rheumatic diseases of childhood. J Rheumatol Suppl 1990;26:7-10.
5. Colbert R A, De Lay M L, Layh-Schmitt G, Sowders D P. HLA-B27 misfolding and spondyloarthropathies. Prion 2009;3(1):15-26.
6. Bowness P. HLA-B27. Annu Rev Immunol 2015;33:29-48.
7. Dean L E, Jones G T, MacDonald A G, Downham C, Sturrock R D, Macfarlane G J. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53(4):650-7.
8. Gunal E K, Sarvan F O, Kamali S, et al. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 2008;75(3):299-302.
9. Nebert D W, Russell D W. Clinical importance of the cytochromes P450. Lancet 2002;360(9340):1155-62.
10. Wang L L, Yong L, Zhou S F. A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450. Drug Metab Dispos 2009;37(5):977-91.
11. Alessandrini M, Asfaha S, Dodgen T M, Warnich L, Pepper M S. Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 2013;45(2):253-75.
12. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner R M. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel) 2020;11(11):1295.
13. Paradkar M U, Shah S A V, Dherai A J, Shetty D, Ashavaid T F. Distribution of CYP2D6 genotypes in the Indian population - preliminary report. Drug Metab Pers Ther 2018;33(3):141-51.
14. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2012;27(1):9-54.
15. Zanger U M, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):23-37.
16. Lu Y, Mo C, Zeng Z, et al. CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis. PLoS One 2013;8(12):e84413.
17. Liou Y H, Lin C T, Wu Y J, Wu L S H. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J Hum Genet 2006;51(10):857.
18. Lee S Y, Sohn K M, Ryu J Y, Yoon Y R, Shin J G, Kim J W. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 2006;28(3):382-7.
19. Teh L K, Ismail R, Yusoff R, Hussein A, Isa M N, Rahman A R. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001;26(3):205-11.
20. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;50(1):31-4.
21. Cai W M, Nikoloff D M, Pan R M, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J 2006;6(5):343-50.
22. Brown M A, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000;9(11):1563-6.
23. Reveille J D. Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20(3):601-9.
24. Sheehan N J. HLA-B27: what's new? Rheumatology (Oxford) 2010;49(4):621-31.
25. Kopplin L J, Mount G, Suhler E B. Review for Disease of the Year: Epidemiology of HLA-B27 Associated Ocular Disorders. Ocul Immunol Inflamm 2016;24(4):470-5.
26. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41(1):58-67.
27. Olivieri I, Barozzi L, Padula A, De Matteis M, Pavlica P. Clinical manifestations of seronegative spondylarthropathies. Eur J Radiol 1998;27 Suppl 1:3-6.
28. Edwards J C, Bowness P, Archer J R. Jekyll and Hyde: the transformation of HLA-B27. Immunol Today 2000;21(6):256-60.
29. Jaakkola E, Herzberg I, Laiho K, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 2006;65(6):775-80.
30. Gul A, Uyar F A, Inanç M, et al. A weak association of HLA-B*2702 with Behçet's disease. Genes Immun 2002;3(6):368-72.
31. Rychlik-Sych M, Baranska M, Waszczykowska E, Torzecka J D, Zebrowska A, Skretkowicz J. Genetic polymorphisms of CYP2D6 oxidation in patients with autoimmune bullous diseases. Postepy Dermatol Alergol 2013;30(4):211-7.
32. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5(1):6-13.
33. Koseler A, Ilcol Y O, Ulus I H. Frequency of mutated allele CYP2D6*4 in the Turkish population. Pharmacology 2007;79(4):203-6.
34. Aydin M, Hatirnaz O, Erensoy N, Ozbek U. CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem Funct 2005;23(2):133-5.
35. Aynacioglu A S, Sachse C, A Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66(2):185-92.
Article Sidebar
Article Details
How to Cite
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
